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Introduction
Preeclampsia is a condition, within the spectrum of  hypertensive 
disorders of  pregnancy, characterized by elevated blood 
pressure and proteinuria, which can progress to involve 
multiple organ systems.[1] The Royal College of  Obstetricians 
and Gynecologists clinically defines preeclampsia as the 
presence of  pregnancy‑induced hypertension (blood pressure 
≥ 140/90 mmHg after 19 weeks of  gestation) and significant 
proteinuria (>0·3 g/24 h).[2] Preeclampsia can be further 
categorized as mild or severe, depending upon the classification 
system that is used.[3] Severe preeclampsia includes severe 
hypertension (≥170/110 mmHg) and heavy proteinuria, and may 
also include other maternal signs of  end‑organ dysfunction.[2]
Across the globe, approximately 800 women die due to preventable 
causes of  pregnancy and childbirth; 99% of  these deaths occur 
in low and middle‑income countries (LMICs).[4] In the early years 
of  the 21st century, the millennium development goals explicitly 
placed maternal health at the core of  the struggle against 
poverty and inequality.[5] Hypertensive disorders of  pregnancy 
are an important cause of  severe morbidity and mortality among 
mothers and infants;[6] and 10% of  all women experience it during 
pregnancy.[7] Globally, preeclampsia is the second‑leading cause 
of  maternal mortality, resulting in an estimated 76,000 maternal 
deaths annually.[6] In addition, 500,000 fetal and newborn 
lives are lost annually due to the perinatal consequences of  
preeclampsia.[6] Moreover, preeclampsia complicates 2–8% 
of  all pregnancies, and 10–15% of  direct maternal deaths are 
associated with preeclampsia and eclampsia.[7] The syndrome of  
hemolysis, elevated liver enzymes and low platelets is a severe 
manifestation of  preeclampsia and complicates approximately 
0.5–0.9% of  all pregnancies and 10–20% of  cases with severe 
preeclampsia.[8] A 20‑fold increase in maternal mortality is 
associated with preeclampsia arising at < 32 weeks compared 
with that at ≥ 37 weeks.[9] According to a systematic review and 
meta‑analysis published in 2007, preeclampsia is associated with 
increased risk of  having hypertension, ischemic heart disease and 
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stroke in later life.[10,11] Overall mortality among women several 
years later was also greater in those who had preeclampsia.[10,12] 
Preeclampsia is also an important cause of  fetal and neonatal 
mortality. Hypertension and/or proteinuria during pregnancy 
have also been associated with stillbirth[13] while preeclampsia is 
strongly associated with fetal growth restriction, low birth weight, 
preterm delivery, respiratory distress syndrome, and admission 
to neonatal intensive care.[14]
There are a number of  hypotheses attempting to explain 
the pathogenesis of  preeclampsia. The definitive cause of  
preeclampsia is generally unknown. Preeclampsia is generally 
considered a two‑stage disorder.[15] It is hypothesized that 
inadequate trophoblast invasion in early pregnancy results in 
impaired placental perfusion, leading to an increase in oxidative 
stress.[16] According to one of  the hypotheses, impaired 
remodeling of  the spiral artery is the basis for this stage of  the 
disease.[17] The later stage of  the disease is the development 
of  systemic endothelial dysfunction, which is responsible for 
the characteristic clinical manifestations of  preeclampsia.[16] 
Underlying metabolic and cardiovascular conditions carry risks 
for endothelial dysfunction themselves, which is why they are 
postulated to play an important role in the pathogenesis of  
late‑onset preeclampsia.[17] It has been proposed that reduced 
placental perfection due to oxidative stress causes endothelial 
dysfunction, hence linking the two stages of  the syndrome.[15] 
There is also a genetic association with a multifactorial polygenic 
inheritance, suggested to play a role in the development of  this 
disease.[16]
Most of  the maternal deaths in LMICs occur at the community‑level 
where the majority of  women do not have access to the health 
care facility. Failure to identify preeclampsia along with a delay 
in responding to the clinical signs and symptoms is responsible 
for nearly half  of  maternal deaths and more than half  of  fetal 
deaths.[13] In community setups, determining the cause of  death 
is difficult, and often reliance is placed on the relatives’ or 
caretakers’ recall of  the symptoms experienced by the women 
prior to death.[18] Hence, there is a need for laying the extensive 
groundwork in development and implementation of  guidelines 
and protocols at the community‑level especially in LMICs. 
Screening and early detection of  preeclampsia in the community 
could lead to a decrease in the preventable mortality of  mother 
and the fetus. Guidelines could be also useful for establishing 
thresholds for referral to specialist care, and assessment 
procedures for suspected preeclampsia cases.
Early Identification and Diagnosis
Prompt diagnosis of  preeclampsia in community settings is 
necessary to ensure maternal and fetal well‑being. Unlike women 
with severe preeclampsia, women with moderate preeclampsia 
generally have no symptoms.[7] Therefore, delays in diagnosis, 
adequate primary care, and referral to a specialist are likely 
to be important contributors of  adverse maternal and fetal 
outcomes.[19]
While there are numerous clinical guidelines for diagnosis 
and management of  preeclampsia in specialist or tertiary care 
centers,[20,21] such is not the case for primary care settings in the 
community.[2] Preeclampsia community guidelines (PRECOG) 
were published in 2005, after having been formulated following 
the National Institute for Clinical Excellence’s (NICE) 
recommendations for the development of  guidelines.[2] This 
guideline makes provisions for assessing risk based on evidence, 
and gives clear criteria for referral to specialist centers, and also 
establishes a schedule for monitoring women in the community 
after 20 weeks’ gestation. Criteria of  referral for step‑up care 
are also given.[2] However, it is important to note that these 
guidelines work best only in health systems of  developed 
nations, and there is a need to contextualize it as per those 
of  LMICs.
Perhaps the most important initial step toward a diagnosis of  
preeclampsia in community settings is the assessment of  risk. 
A meta‑analysis by Duckitt and Harrington showed that the 
risk of  preeclampsia is increased in women with a previous 
history of  preeclampsia (relative risk 7.19) and in those with 
anti‑phospholipids antibodies (relative risk 9.72) and preexisting 
diabetes (relative risk 3.56).[22] Patients with multiple pregnancy, 
nulliparity, family history, raised body mass index before 
pregnancy and maternal age > 40 for multiparous women 
were shown to have increased the risk for preeclampsia as 
well.[22] A population‑based retrospective study from Canada also 
concluded an approximately seven‑fold higher risk of  recurrent 
severe preeclampsia among women who has severe preeclampsia 
in previous pregnancy (6.8%; 95% confidence interval 5.7–
7.9%).[23] Moreover, a history of  early‑onset preeclampsia is 
associated with increased odds of  adverse pregnancy outcomes 
despite a normotensive second pregnancy.[24]
According to the PRECOG assessment of  risk should be 
performed before 20 weeks of  gestation and women should 
be referred for expert evaluation by specialist if  they have 
either had a previous preeclampsia, a multiple pregnancy, 
preexisting underlying medical conditions like renal disease or 
chronic hypertension or any two other risk factors from a list.[2] 
Complete absence of  antenatal care is known to be strongly 
associated with fetal death.[25] However, there is no evidence 
to recommend special antenatal care in addition to routine, to 
women who might be at risk for preeclampsia but otherwise 
do not qualify for specialist referral according to PRECOG 
criteria.[26] It is possible for women with no risk factors for 
preeclampsia to develop the condition. NICE recommends 
assessment for preeclampsia at weeks 16, 28, 34, 36, 38, 
40, and 41 for healthy parous women with a single fetus.[27] 
However, such rigorous schedule of  hospital visits might not 
be implementable in a LMIC nation where health systems 
are overburdened at one end and patients themselves find it 
difficult to visit healthcare facilities due to cost and distance 
considerations. There is an immense role that community 
healthcare workers can play in this arena and future research 
should be directed to this issue.
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Assessments done after 20 weeks’ gestation, by identifying 
possible onset of  preeclampsia from signs and symptoms 
including new hypertension, new proteinuria, symptoms of  
headache, visual disturbance, epigastric pain, vomiting, reduced 
fetal movements, and an infant that is small for gestational age 
can help identifying high‑risk cases for referral to specialist care.[28] 
In the community, fetal compromise is usually assessed by asking 
women about reduced fetal movements or by assessment for 
small for gestational age fetus.[2]
The World Health Organization (WHO) antepartum care model 
calls for a blood pressure check in the second antenatal visit in 
addition to testing for proteinuria in nulliparous women or in 
women with previous preeclampsia.[29] The method of  measuring 
blood pressure is critical: Errors have been implicated in maternal 
deaths.[2] Regular maintenance and calibration checks are vital 
in ensuring that blood pressure is measured as accurately as 
possible. A large of  number of  devices in use may have an 
unacceptable calibration error.[30] The effective management 
requires measurement and monitoring of  blood pressure. 
Low‑cost self‑measurement oscillometric devices, with features 
suitable for use in an adult population in a low‑resource setting 
in the LMICs, have shown to be acceptable.[31] While both 
inflationary and deflationary oscillometry devices are acceptable 
for measuring blood pressure, it is possible that inflationary 
oscillometry is more accurate for screening for hypertension in 
pregnant women with preeclampsia.[32] In conclusion, measuring 
blood pressure and proteinuria is challenging in low‑resource 
settings due to the financial cost and lack of  training. Significant 
training is needed to measure blood pressure accurately, along 
with the availability of  well‑maintained equipment, both of  which 
pose a challenge to the early identification of  preeclampsia in 
community settings. A detection tool that is affordable and can 
be easily applied is needed.[33]
Numerous clinical, biophysical, and biochemical screening tests 
have been proposed for the early detection of  preeclampsia over 
the past decades. However, discrepancies have been reported in 
their sensitivity and predictive value. No single screening test used 
for preeclampsia prediction has gained widespread acceptance 
into clinical practice.[34] It is important to identify at‑risk women 
in the community and building the capacity of  the caregivers in 
community and staff  at the primary health centers to manage 
women with preeclampsia and eclampsia at the primary care level 
itself. Only those that develop complications should be referred 
to prevent overburdening of  tertiary care facilities.
Prevention
The causes of  preeclampsia are still largely debatable and mostly 
unknown. Hence, it is difficult to formulate strategies for effective 
primary prevention at this stage. Research in the past decade 
has identified some major risk factors for preeclampsia, and 
identification and modification of  these factors might result in 
a decrease in its frequency.[35,36] Advanced maternal age, obesity, 
and no utilization of  prenatal care are the risk factors identified 
for preeclampsia.[37] Overweight and obese women have an 
increased risk for preeclampsia, while underweight women have 
an increased risk for preterm delivery.[38] There is some evidence 
that secondary prevention with calcium supplementation and 
aspirin administration during pregnancy are beneficial in women 
with low calcium intake, and at a very high risk of  developing 
severe early onset disease, respectively.[35]
Anti‑platelet agents, especially low‑dose aspirin, have small‑moderate 
benefits when used for prevention of  preeclampsia. When 
anti‑platelet agents were compared to placebo or no agent, there 
was a 17% reduction in the risk of  preeclampsia associated with the 
use of  anti‑platelet agents.[39] There was a small (8%) reduction in 
the risk of  delivery before 37 completed weeks. Overall there was a 
14% reduction in baby deaths in the anti‑platelet group. There was 
a 10% reduction in risk of  small‑for‑gestational age babies. There 
is a need for further research to assess women, which are likely 
to benefit most from such interventions and to identify best time 
of  starting treatment, as well as optimal dosing.[39] A meta‑analysis 
that assessed the influence of  starting aspirin before 16 weeks 
of  gestation found a 52% reduction in the risk of  preeclampsia 
compared with the control group, however no difference was 
observed when started after 16 weeks.[40]
Calcium supplementation during pregnancy, when compared 
with placebo, appears to approximately halve the risk of  
preeclampsia.[41] It also reduces the risk of  preterm birth and 
occurrence of  death or serious morbidity.[41] However, it is 
of  note that existing evidence shows that only women with a 
low dietary calcium intake are likely to benefit from calcium 
supplementation.[36] Since most pregnant women in LMICs are 
deficient in calcium, calcium supplementation is an intervention 
of  interest for LMICs.[33] Other dietary nutritional measures, 
including administration of  Vitamin C and other anti‑oxidants, 
or drugs have not shown clear, irrefutable benefit, and there is 
insufficient evidence to recommend clinical use.[35]
Management
The goal of  managing preeclampsia is to keep blood pressure of  
woman in the normal range with anti‑hypertensives and prevent 
the development of  complications like eclampsia. Delivery of  the 
fetus and placenta is the only definitive treatment for preeclampsia 
but the option, is sadly not available for most patients who are 
diagnosed before the baby is full‑term. Treatment is largely 
symptomatic with monitoring for development of  complications. 
Once blood pressure increases above a certain level, it may lead 
to direct vascular damage, which in turn leads to life‑threatening 
complications such as renal failure, stroke, and fetal distress.[7] 
Thus for women with severe preeclampsia, before 34 weeks of  
gestation, expectant management is recommended, such that 
maternal hypertension is under control, and maternal organ 
dysfunction or fetal distress is absent and can be monitored. 
However, the evidence‑based behind expectant management for 
decreasing neonatal morbidity is small and based on data from 
only limited number of  trials.[42]
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There is no clear drug of  choice for use during hypertensive 
disorders of  pregnancy. In contrast to nonsevere hypertension, 
severe hypertension (defined as systolic blood pressure 
160 and/or diastolic blood pressure 110) must be treated. 
The Confidential Inquiry into Maternal and Child Health 
highlighted the importance of  treating severe hypertension and 
demonstrated that the failure of  anti‑hypertensive therapy was 
the most common source of  sub‑standard care even in high 
resource settings.[13] The choice of  anti‑hypertensive however is 
largely guided by the clinicians experience and familiarity with 
a particular drug[43] and on what is known about adverse effects 
and teratogenic potential due to lack of  good quality evidence 
from trials.
The full intravenous or intramuscular regimen of  magnesium 
sulfate is the drug of  choice for both prevention of  eclampsia 
in severe preeclampsia cases as well as treatment of  eclampsia. 
In the United Kingdom, widespread uptake of  magnesium 
sulfate is thought to account for the decline in the incidence 
of  eclampsia.[44] In LMICs healthcare access is poor and 
routine antenatal coverage is not universal or of  poor quality 
resulting in most patients visiting a clinician at the stage of  
severe preeclampsia or eclampsia. Such cases are an obstetric 
emergency considering the impending danger to the mother 
and the baby. Magnesium sulfate has been found to be 
beneficial to use in terms of  significantly decreased the risk of  
eclampsia (about half) and risk of  placental abruption (more than 
half) when compared with placebo or no anti‑convulsant.[44,45] 
Use of  magnesium sulfate in the community is however 
limited because of  apprehension among healthcare workers 
about its safety. This, despite its clear effectiveness, low‑cost, 
and being on the essential medicines for most countries, if  
not all.[46,47] Toxicity can be monitored clinically by respiratory 
rate, urine output and deep tendon reflexes. Limited provider 
knowledge and training, and lack of  national guidelines and 
protocols and sociocultural factors and various other factors 
for underutilization of  magnesium sulfate has already been 
identified.[33,48] For primary care facilities where full schedule 
of  magnesium sulfate cannot be given or when development 
of  further complications is anticipated, WHO recommends 
giving the loading dose of  magnesium followed by referral to 
a higher level health‑care facility.[49] Health care worker training 
and confidence building measures are hence an important part 
of  the strategy for controlling the problem of  preeclampsia. 
Trials comparing alternative regimens of  magnesium sulfate 
for preeclampsia are of  poor quality‑too small and unreliable 
for making any conclusions and hence its clinical use not 
recommended.[50]
Conclusions
Evidence exists that a series of  strategies including standardized 
assessment and surveillance, adequate management of  severe 
hypertension, and prevention of  eclampsia have the potential 
for reducing risks of  adverse maternal outcomes in women with 
preeclampsia.[51] However, this involves a full detailed work‑up in 
addition to the routine clinical tests done and hence might be not 
feasible in terms of  costs as well as implementation in LMICs. 
Furthermore, intervention delivery and targeting the ones at 
high risk are a major issue in many LMICs. Despite the existing 
proven interventions to prevent and manage preeclampsia and 
eclampsia, effective delivery strategies still remain unexplored. 
Access to health care, distance, and cost are major obstacles 
for women in LMICs to seek care for preeclampsia. Antenatal 
care utilization is around 68% in LMICs compared with 98% 
in high resource settings.[33] The region of  the world with the 
lowest levels of  use is South Asia, where only 54% of  pregnant 
women have at least one antenatal care visit.[52] Though the 
principles of  care for women with preeclampsia remain the 
same globally, there is a need to adapt guidelines in the context 
of  these and other problems unique to LMICs. Delays in 
identification, transport, and initiation of  treatment because 
of  number of  factors lead to additional health system issues 
and this need to be accounted when contextualizing evidence 
regarding preeclampsia in LMICs.
One of  the ways forward, especially for the LMICs, could be 
scaling up of  existing community‑based delivery platforms for 
screening and delivering intervention strategies. Many LMICs 
have an existing cadre of  community health workers (CHWs) 
for example Shasthyo Sebikas (Bangladesh), Village Health 
Worker (Bhutan), Village Health Guide (India), Female 
Community Health Volunteer (Nepal), and Lady Health 
Visitor (Pakistan). These existing cadres could be utilized for 
screening and early referrals to prevent delays in identification 
and treatment. Evidence from Bangladesh, a typical LMIC, 
clearly indicates that outcomes were better for community‑based 
maternal care programs implemented by posting trained midwives 
posted in villages at primary health care system.[53] There are 
successful examples from Pakistan where CHWs workers 
and midwives have been trained to administer misoprostol in 
women with postpartum hemorrhage.[54] This is supportive to 
of  the recommendation that with proper training, it is feasible 
to incorporate even emergency medication administration in 
community settings where accessibility and availability are an 
issue.
Such an approach is also reasonable as CHWs are already 
functioning within the communities to deliver health promotion, 
preventive care and essential curative maternal, newborn child 
health services. Furthermore, there is a significant amount of  
community acceptability of  these workers. However, there is 
a need to train these CHWs on the concepts related to the 
prevention and management of  preeclampsia and eclampsia 
specifically. There is also a need for focused primary care 
funding to evaluate success of  such programs before large‑scale 
implementation can be done – especially with regard to 
conditions like preeclampsia and eclampsia, which turn to 
emergencies within a very short span of  time. Such efforts thus 
need to be supplemented by the development of  rapid and 
effective emergency care facilities and capacity building of  health 
facilities where women are being referred to.
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It is important to note that there is a need to shift from the current 
approach of  either ‘vertical’ programs (which only aim at reducing 
disease‑specific targets) or “horizontal” programs (which only 
aim at solving health system issues and consequently more time 
consuming and difficult to implement).[55] For better maternal 
and child care it is important to take a “diagonal approach” as 
of  now and also aim at focused research at primary care level to 
improve the evidence base for it.
References
1. Davey DA, MacGillivray I. The classification and definition 
of the hypertensive disorders of pregnancy. Am J Obstet 
Gynecol 1988;158:892‑8.
2. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, 
et al. The pre‑eclampsia community guideline (PRECOG): 
How to screen for and detect onset of pre‑eclampsia in the 
community. BMJ 2005;330:576‑80.
3. Brown MA, Buddle ML. What’s in a name? Problems with 
the classification of hypertension in pregnancy. J Hypertens 
1997;15:1049‑54.
4. World Health Organization. Maternal Mortality: Fact 
Sheet. Available from: http://www.who.int/mediacentre/
factsheets/fs348/en/. [Last accessed on 2015 Feb 05].
5. Högberg U. The World Health Report 2005: Make every 
mother and child count – Including Africans. Scand J Public 
Health 2005;33:409‑11.
6. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. 
WHO analysis of causes of maternal death: A systematic 
review. Lancet 2006;367:1066‑74.
7. Duley L. The global impact of pre‑eclampsia and eclampsia. 
Semin Perinatol 2009;33:130‑7.
8. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: 
Clinical issues and management. A Review. BMC Pregnancy 
Childbirth 2009;9:8.
9. MacKay AP, Berg CJ, Atrash HK. Pregnancy‑related mortality 
from preeclampsia and eclampsia. Obstet Gynecol 
2001;97:533‑8.
10. Bellamy L, Casas JP, Hingorani AD, Williams DJ. 
Pre‑eclampsia and risk of cardiovascular disease and 
cancer in later life: Systematic review and meta‑analysis. 
BMJ 2007;335:974.
11. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. 
Cardiovascular disease risk in women with pre‑eclampsia: 
Systematic review and meta‑analysis. Eur J Epidemiol 
2013;28:1‑19.
12. Skjaerven R, Wilcox AJ, Klungsøyr K, Irgens LM, Vikse BE, 
Vatten LJ, et al. Cardiovascular mortality after pre‑eclampsia 
in one child mothers: Prospective, population based cohort 
study. BMJ 2012;345:e7677.
13. Weindling AM. The confidential enquiry into maternal and 
child health (CEMACH). Arch Dis Child 2003;88:1034‑7.
14. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, 
et al. Do women with pre‑eclampsia, and their babies, benefit 
from magnesium sulphate? The Magpie Trial: A randomised 
placebo‑controlled trial. Lancet 2002;359:1877‑90.
15. Roberts JM. Preeclampsia: What we know and what we do 
not know. Semin Perinatol 2000;24:24‑8.
16. Valenzuela FJ, Pérez‑Sepúlveda A, Torres MJ, Correa P, 
Repetto GM, Illanes SE. Pathogenesis of preeclampsia: The 
genetic component. J Pregnancy 2012;2012:632732.
17. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. 
Pre‑eclampsia. Lancet 2010;376:631‑44.
18. Lewis G. Beyond the numbers: Reviewing maternal deaths 
and complications to make pregnancy safer. Br Med Bull 
2003;67:27‑37.
19. Thaddeus S, Maine D. Too far to walk: Maternal mortality 
in context. Soc Sci Med 1994;38:1091‑110.
20. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, 
McMahon LP, et al. Guidelines for the management of 
hypertensive disorders of pregnancy 2008. Aust N Z J Obstet 
Gynaecol 2009;49:242‑6.
21. Magee LA, Helewa M, Moutquin JM, von Dadelszen P; 
Hypertension Guideline Committee; Strategic Training 
Initiative in Research in the Reproductive Health 
Sciences (STIRRHS) Scholars. Diagnosis, evaluation, and 
management of the hypertensive disorders of pregnancy. 
J Obstet Gynaecol Can 2008;30 3 Suppl: S1‑48.
22. Duckitt K, Harrington D. Risk factors for pre‑eclampsia at 
antenatal booking: Systematic review of controlled studies. 
BMJ 2005;330:565.
23. McDonald SD, Best C, Lam K. The recurrence risk of 
severe de novo pre‑eclampsia in singleton pregnancies: 
A population‑based cohort. BJOG 2009;116:1578‑84.
24. Chang JJ, Muglia LJ, Macones GA. Association of early‑onset 
pre‑eclampsia in first pregnancy with normotensive second 
pregnancy outcomes: A population‑based study. BJOG 
2010;117:946‑53.
25. Abi‑Said D, Annegers JF, Combs‑Cantrell D, Frankowski RF, 
Willmore LJ. Case‑control study of the risk factors for 
eclampsia. Am J Epidemiol 1995;142:437‑41.
26. Carroli G, Villar J, Piaggio G, Khan‑Neelofur D, Gülmezoglu 
M, Mugford M, et al. WHO systematic review of randomised 
controlled trials of routine antenatal care. Lancet 
2001;357:1565‑70.
27. National Institute of Health and Clinical Experience. 
Antenatal Care: Routine Care for the Healthy Pregnant 
Woman, Clinical Guidelines. London: National Institute of 
Health and Clinical Experience; 2008.
28. Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, 
et al. Assessing the onset of pre‑eclampsia in the hospital 
day unit: Summary of the pre‑eclampsia guideline (PRECOG 
II). BMJ 2009;339:b3129.
29. Villar J, Ba’aqeel H, Piaggio G, Lumbiganon P, Miguel Belizán J, 
Farnot U, et al. WHO antenatal care randomised trial for the 
evaluation of a new model of routine antenatal care. Lancet 
2001;357:1551‑64.
30. de Greeff A, Lorde I, Wilton A, Seed P, Coleman AJ, 
Shennan AH. Calibration accuracy of hospital‑based 
non‑invasive blood pressure measuring devices. J Hum 
Hypertens 2010;24:58‑63.
31. Duhig KE, De Greeff A, Van Der Westhuizen A, Baker E, 
Shennan AH. Validation of the Nissei DS‑400 in a 
low‑resource setting. Blood Press Monit 2009;14:132‑5.
32. de Greeff A, Beg Z, Gangji Z, Dorney E, Shennan AH. 
Accuracy of inflationary versus deflationary oscillometry 
in pregnancy and preeclampsia: OMRON‑MIT versus 
OMRON‑M7. Blood Press Monit 2009;14:37‑40.
33. Firoz T, Sanghvi H, Merialdi M, von Dadelszen P. 
Pre‑eclampsia in low and middle income countries. Best 
Pract Res Clin Obstet Gynaecol 2011;25:537‑48.
34. Costa Fda S, Murthi P, Keogh R, Woodrow N. Early screening 
for preeclampsia. Rev Bras Ginecol Obstet 2011;33:367‑75.
[Downloaded free from http://www.jfmpc.com on Tuesday, September 25, 2018, IP: 221.132.113.70]
Salam, et al.: Preeclampsia in community settings 
Journal of Family Medicine and Primary Care 506 October 2015 : Volume 4 : Issue 4
35. Briceño‑Pérez C, Briceño‑Sanabria L, Vigil‑De Gracia P. 
Prediction and prevention of preeclampsia. Hypertens 
Pregnancy 2009;28:138‑55.
36. Dekker G, Sibai B. Primary, secondary, and tertiary 
prevention of pre‑eclampsia. Lancet 2001;357:209‑15.
37. Fang R, Dawson A, Lohsoonthorn V, Williams MA. Risk 
factors of early and late onset preeclampsia among Thai 
women. Asian Biomed (Res Rev News) 2009;3:477‑86.
38. Hauger MS, Gibbons L, Vik T, Belizán JM. Prepregnancy 
weight status and the risk of adverse pregnancy outcome. 
Acta Obstet Gynecol Scand 2008;87:953‑9.
39. Duley L, Henderson‑Smart DJ, Meher S, King JF. Antiplatelet 
agents for preventing pre‑eclampsia and its complications. 
Cochrane Database Syst Rev 2007 ;2:CD004659.
40. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, 
Giguère Y. Acetylsalicylic acid for the prevention of 
preeclampsia and intra‑uterine growth restriction in women 
with abnormal uterine artery Doppler: A systematic review 
and meta‑analysis. J Obstet Gynaecol Can 2009;31:818‑26.
41. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. 
Calcium supplementation during pregnancy for preventing 
hypertensive disorders and related problems. Cochrane 
Database Syst Rev 2014;6:CD001059.
42. Churchill D, Duley L, Thornton JG, Jones L. Interventionist 
versus expectant care for severe pre‑eclampsia between 
24 and 34 weeks’ gestation. Cochrane Database Syst Rev 
2013;7:CD003106.
43. Duley L, Henderson‑Smart DJ, Meher S. Drugs for treatment 
of very high blood pressure during pregnancy. Cochrane 
Database Syst Rev 2006;3:CD001449.
44. Knight M; UKOSS. Eclampsia in the United Kingdom 2005. 
BJOG 2007;114:1072‑8.
45. Duley L, Gülmezoglu AM, Henderson‑Smart DJ, Chou D. 
Magnesium sulphate and other anticonvulsants for 
women with pre‑eclampsia. Cochrane Database Syst Rev 
2010 ;11:CD000025.
46. Aaserud M, Lewin S, Innvaer S, Paulsen EJ, Dahlgren AT, 
Trommald M, et al. Translating research into policy and 
practice in developing countries: A case study of magnesium 
sulphate for pre‑eclampsia. BMC Health Serv Res 2005;5:68.
47. Simon J, Gray A, Duley L; Magpie Trial Collaborative 
Group. Cost‑effectiveness of prophylactic magnesium 
sulphate for 9996 women with pre‑eclampsia from 33 
countries: Economic evaluation of the Magpie Trial. BJOG 
2006;113:144‑51.
48. Bigdeli M, Zafar S, Assad H, Ghaffar A. Health system 
barriers to access and use of magnesium sulfate for women 
with severe pre‑eclampsia and eclampsia in Pakistan: 
Evidence for policy and practice. PLoS One 2013;8:e59158.
49. WHO. WHO Recommendations for Prevention and Treatment 
of Pre‑eclampsia and Eclampsia. Geneva, Switzerland: World 
Health Organization; 2011. Available from: http://www.
whqlibdoc.who.int/publications/2011/9789241548335_
eng.pdf. [Last cited on 2015 Mar 12].
50. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative 
magnesium sulphate regimens for women with 
pre‑eclampsia and eclampsia. Cochrane Database Syst Rev 
2010 ;8:CD007388.
51. Menzies J, Magee LA, Li J, MacNab YC, Yin R, Stuart H, et al. 
Instituting surveillance guidelines and adverse outcomes 
in preeclampsia. Obstet Gynecol 2007;110:121‑7.
52. Abdou‑Zahar CL, Wardlaw TM. Antenatal care in developing 
countries: Promises, achievements and missed opportunities: 
an analysis of trends, levels and differentials, 1990‑2001. 
WHO: Geneva, Switzerland; 2003.
53. Fauveau V, Stewart K, Khan SA, Chakraborty J. Effect on 
mortality of community‑based maternity‑care programme 
in rural Bangladesh. Lancet 1991;338:1183‑6.
54. Mobeen N, Durocher J, Zuberi N, Jahan N, Blum J, Wasim S, 
et al. Administration of misoprostol by trained traditional 
birth attendants to prevent postpartum haemorrhage in 
homebirths in Pakistan: A randomised placebo‑controlled 
trial. BJOG 2011;118:353‑61.
55. Ooms G, Van Damme W, Baker BK, Zeitz P, Schrecker T. 
The ‘diagonal’ approach to Global Fund financing: A cure 
for the broader malaise of health systems? Global Health 
2008;4:6.
How to cite this article: Salam RA, Das JK, Ali A, Bhaumik S, Lassi ZS. 
Diagnosis and management of preeclampsia in community settings in 
low and middle-income countries. J Family Med Prim Care 2015;4:501-6.
Source of Support: Nil. Conflict of Interest: None declared.
[Downloaded free from http://www.jfmpc.com on Tuesday, September 25, 2018, IP: 221.132.113.70]
